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Objective: To review the literature on the role and regulation of chondrocyte terminal differentiation
(hypertrophy-like changes) in osteoarthritis (OA) and to integrate this in a conceptual model of primary
OA development.
Methods: Papers investigating chondrocyte terminal differentiation in human OA cartilage and experi-
mental models of OA were recapitulated and discussed. Focus has been on the occurrence of
hypertrophy-like changes in chondrocytes and the factors described to play a role in regulation of
chondrocyte hypertrophy-like changes in OA.
Results: Chondrocyte hypertrophy-like changes are reported in both human OA and experimental OA
models by most investigators. These changes play a crucial part in the OA disease process by protease-
mediated cartilage degradation. We propose that altered chondrocyte behavior and concomitant
cartilage degradation result in a disease-amplifying loop, leading to a mixture of disease stages and
cellular responses within an OA joint.
Conclusion: Chondrocyte hypertrophy-like changes play a role in early and late stage OA. Since not all
cells in an OA joint are synchronized, inhibition of hypertrophy-like changes might be a therapeutic
target to slow down further OA progression.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is the most common joint disease and highly
associated with age. This disease is characterized by a change in
chondrocyte behavior that leads to elevated production of proteo-
lytic enzymes, such as matrix metalloproteinase13 (MMP13), and
consequently to cartilage damage and loss of joint function.
However, one has to keep in mind that alternative routes are
proposed that can lead to OA, amongst others mechanical wear and
tear, bone changes and changes in the cartilage extracellularmatrix.
Changes in chondrocyte behavior, such as expression of hyper-
trophy markers and matrix calciﬁcation, frequently resemble the
phenomena observed in the hypertrophic layer of the growth plate
of long bones, but other phenotypic changes are also reported1. In
this article, we will discuss the occurrence and role of chondrocyte
hypertrophy-like changes in (experimental) OA. Discussed will be
cartilage calciﬁcation, apoptosis, autophagy, transgenic and knock
out mouse models, and factors involved in regulation ofM. van der Kraan, Department
, Geert Grooteplein 28, 6525
31-24-3540403.
M. van der Kraan).
s Research Society International. Phypertrophy-like changes. Finally, wewill put forward a theoretical
model of OA development and the part that hypertrophy-like
changes play in this disease.Chondrocyte differentiation
Hyaline cartilage can be largely divided into temporary and
permanent cartilage. Temporary hyaline cartilage is found in the
embryonic stages of endochondral bones and the growth plate and
is ﬁnally replaced by bone. Permanent hyaline cartilage, present
amongst others in articulating joints, does not undergo terminal
differentiation under normal conditions. The cellular origin of both
types of temporary and permanent cartilage is similar. As
concluded from both in vivo and in vitro studies, the default route of
chondrocyte differentiation is terminal differentiation (hyper-
trophy and apoptosis)2e7. An enlightening in vivo model of adult
chondrocyte differentiation is osteophyte formation8. Osteophytes
are the result of chondrogenic differentiation of mesenchymal stem
cells in the periosteum. Initially cartilage is formed but the ﬁnal
product is bone. Apparently, unrestricted differentiation of
precursor cells into the chondrocyte lineage does not lead to
permanent cartilage but to bone. In articular cartilage, this default
route is somehow blocked to obtain permanent cartilage.ublished by Elsevier Ltd. All rights reserved.
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actively produce cartilage-degrading enzymes, such MMP13 and
aggrecanases9e13. The exact activation mechanism of chondrocytes
in OA cartilage is not understood. Age-related changes in the
extracellular matrix molecules or activation by inﬂammatory
cytokines, like IL-1, might play a role in direct activation of the
chondrocytes as recently discussed14e16. Alternatively, the altered
phenotype might be the result of articular chondrocytes taking
a differentiation route resembling that of growth plate chon-
drocytes, expressing hypertrophy-like changes. This will be
accompanied by acquisition of an autolytic phenotype by the
chondrocytes resulting in destruction of the surrounding cartilage.
The occurrence of chondrocyte hypertrophy-like changes in OA is
discussed below.
Indications for chondrocyte hypertrophy-like changes in OA
The exact pathogenic mechanism of OA is still not elucidated, if
there is at all a general, major mechanism. It can be anticipated that
more than one road leads to cartilage destruction and loss of joint
function. This can be different for different OA subgroups. A route
that has been proposed is that articular chondrocyte loose their
differentiated phenotype and obtain a behavior with similarities to
terminal differentiating chondrocytes (hypertrophy-like), as can be
found in the growth plate of growing individuals17,18.
Markers of hypertrophic chondrocytes are several, the most
widely used are type X collagen and MMP1319e21. However,
osteopontin, osteocalcin, Indian Hedgehog, Runx2, VEGF, HtrA1
and transglutaminase-2 (TG-2) are all shown to be associated with
chondrocyte hypertrophy22e28. However, one has to keep in mind
that, although accepted as a hypertrophy marker, MMP13 synthesis
is induced in chondrocytes by alternative routes, such as inﬂam-
mation and mechanical stress16,29,30.
The ultimate end stage of chondrocyte hypertrophy is calcium
deposition. This state has not necessarily to be reached in OA
cartilage. More important for the disease initiation and progression
is the fact that hypertrophic chondrocytes degrade their
surroundings, as can be seen in OA. What is more, cartilage calci-
ﬁcation does not have to be unavoidably related to chondrocyte
hypertrophy. However, calciﬁcation of articular cartilage appears to
be associated with elevated expression of hypertrophy markers31.
Calciﬁcation of articular cartilage
Calciﬁcation of articular cartilage and ossiﬁcation as a result of
terminal differentiation of chondrocytes might be different
processes, but a number of studies have indicated overlapping
phenomena. Studies in the sixties and seventies of the last century
have shown that in human cartilage the number of tidemarks, the
line bordering the calciﬁed cartilage and the non-calciﬁed cartilage,
is increased above the age of 6032,33. This movement of the tide-
mark to the cartilage surface should result in an increase in the
thickness of the calciﬁed cartilage, but it is shown that instead the
calciﬁed zone becomes thinner during aging. This indicates
replacement of the lower calciﬁed cartilage by bone because of
endochondral ossiﬁcation.
Not only aging, but also OA is related to ossiﬁcation processes in
articular cartilage. Next to increased alkaline phosphates and pyro-
phosphate levels, calciﬁcation is a common observation in OA34e38.
Not only in large joints, but also degenerative changes in interver-
tebral discs have been associated with tissue calciﬁcation39,40.
Articular cartilage calciﬁcation is not always easily identiﬁed by
X-ray, but Fuerst et al. showed the presence of calciﬁcations in all
examined OA cartilage samples by digital contact radiography31. In
these studies, severity ofOAcorrelatedpositivelywith the amountofmatrix calciﬁcation and basic calcium phosphate was identiﬁed as
the principal mineral. In cell culture experiments, OA chondrocytes
showed a strong correlation between their ability to produce
calciumphosphate invitro and the extentofmineralizationobserved
in the donors. Furthermore, induction of hypertrophy-like changes
in healthy human chondrocytes led to unambiguous calciﬁcation of
the extracellular matrix31,41,42.
However, others have concluded that calciﬁcation of OA artic-
ular cartilage is related to age instead of OA itself43. This is mainly
based on the observation that no further increase in cartilage
calcium levels was observed when OA structural changes increased
from moderate to severe. From these data, it could also be
concluded that calciﬁcation is a rather early phenomenon and does
not further increase in end-stage OA. In addition, age is the main
risk factor for OA development and age-related calciﬁcation points
to an age-related underlying mechanism, coupling calciﬁcation and
cartilage damage.
Markers for chondrocyte hypertrophy-like changes in human
cartilage
Type X collagen is considered as the standard marker for
chondrocyte hypertrophy. The function of type X collagen is still not
clear but its expression at sites of chondrocyte hypertrophy and
calciﬁcation suggest a role in the early stage of endochondral bone
formation. Type X collagen is normally not expressed in human
healthy articular cartilage but its expression is detected at protein
and mRNA level in human OA cartilage17,44e50. Particularly in the
vicinity of lesions, COL10A1 has been shown to be up regulated51. In
a study of Fukui et al., studying the regional and zonal differences in
gene expression in OA cartilage, it was demonstrated that overall
expression of COL10A1 was elevated but that expression showed
signiﬁcant local variation. Notably, the expression of type COL10A1
was higher in the less degenerated than in the more degenerated
areas52,53. However, a number of expression array studies, both in
human and experimental OA, have failed to detect elevated
COL10A1 expression in OA cartilage47,48,54. Sampling differences,
zonal differences and stage dependent alterations might explain
these differences. An alternative explanation is that chondrocyte
hypertrophy-like changes are not a general phenomenon in human
OA but only observed in a subgroup of human OA patients.
Anothermarker of hypertrophy, collagenase-3 orMMP13, is also
frequently shown to be elevated in OA cartilage9,10,55,56. Up regu-
lation of MMP13 by more than 40-fold in OA cartilage compared to
normal cartilage was shown by microarray and RT-PCR52. More-
over, even investigators that did not report an elevation of COL10A1
expression clearly demonstrated increased expression of MMP13 in
OA cartilage48,57, which appears to indicate that MMP13 and type X
collagen expression are uncoupled and MMP13 expression can be
elevated by alternative pathways than chondrocyte terminal
differentiation.
Other genes or proteins, related to chondrocyte hypertrophy,
that have been demonstrated to be more highly expressed in OA
cartilage than normal cartilage are amongst others; osteocalcin50,
osteopontin58, osteonectin59, Indian Hedgehog51, Runx260, VEGF61,
beta-catenin62, alkaline phosphatase59. Expression of Sox9,
a crucial transcription factor for chondrocytes, is down regulated in
human OA cartilage as is observed in terminal differentiating
growth plate chondrocytes48,60,63,64.
Hypertrophic chondrocytes in the growth plate do not only
express speciﬁc molecules such as type X collagen, but also
undergo apoptosis to make bone deposition possible65. Apoptosis
can be considered as a marker for chondrocyte hypertrophy in OA
cartilage66. Chondrocytes in human OA cartilage have demon-
strated elevated Tunel staining and express the apoptosis markers,
Table I
Regulators of chondrocyte hypertrophy and OA
Hypertrophy
regulators
Function/Action Ref.
Runx2 Master transcription factor in chondrocyte
hypertrophic differentiation
11,78,82
HIF2-alpha Transcription factor in chondrocyte
hypertrophic differentiation
C/EBPbeta Transcription factor in chondrocyte
hypertrophic differentiation
83,84
GADD45beta Stimulating factor in chondrocyte
hypertrophic differentiation, via C/EBPbeta
85
Nfat1 Transcription factor in chondrocyte
hypertrophic differentiation
86e89
b-catenin Transcription factor in chondrocyte
hypertrophic differentiation
Smad2/3 Blocks Runx2 function 90,103e106,112,113
Smad1/5/8 Stimulates Runx2 function 90,103e106,112,113
DDR2 Collagen receptor, modulation of
Runx2 action
118
Matrilin-3 Extracellular matrix molecule 122
SirT1 Histone deacetylase, transcription regulator 124
TG-2 Extracellular cross-linking enzyme 23,127
Interleukin-8 Cytokine regulating chondrocyte
hypertrophic differentiation
108
S100 proteins Ca-binding proteins 109
P.M. van der Kraan, W.B. van den Berg / Osteoarthritis and Cartilage 20 (2012) 223e232 225annexin II and V, caspase-3 and -9, BCL-2 and FAS49,67e69. More-
over, caspase inhibitors reduce severity of cartilage lesions in
experimental models of OA70. However, the role of apoptosis in OA
remains enigmatic. Some studies show such a high number of
apoptotic cells that this is hard to merge with a slowly progressive
disease. Nevertheless, the abundant presence of apoptosis markers
in OA chondrocytes suggests a phenotype that resembles that of
terminally differentiated hypertrophic chondrocytes.
A process related to apoptosis and that has attracted increasing
attention in OA is autophagy. Hypertrophic chondrocytes in the
growth plate have been shown to undergo autophagy71. Autophagy
has been put forward as an alternative cause of chondrocyte cell
death in OA72. In contrast, autophagy could be a cartilage protective
mechanismwhich is lost upon aging and OA development73,74. The
exact role of autophagy in chondrocyte hypertrophy and OA is not
elucidated yet but will be an important subject of investigation in
the coming years.
Markers for chondrocyte hypertrophy-like changes in OA
models
Little is known about chondrocyte hypertrophy and sponta-
neous age-related OA in animal models. However, increased
expression of chondrocyte hypertrophy markers has been observed
in OA cartilage of aging OA-prone Hartley guinea pigs and horses
with OA show chondrocyte apoptosis25,75,76. Somewhat more
information is available about the occurrence of these markers in
induced OA models. Hypertrophy markers have been observed in
several models of OA in different species. In mice, in which OA was
induced by provoking knee joint instability by transection of knee
ligaments and removal of the medial meniscus, elevated expression
of MMP13 and type X collagen was reported77,78. Rats that under-
went anterior cruciate transection and forced mobilization
expressed alkaline phosphatase, MMP13 and type X collagen in the
affected knee joints79. Medial meniscectomy in larger animals such
as sheep resulted in chondrocyte hypertrophy-like changes in the
OA cartilage after 6 months80. These observations indicate that
chondrocyte hypertrophic changes in OA cartilage are not limited to
humans and can be observed in both small and large animals. In
mice, regulation of chondrocyte hypertrophy and its relation with
OA development have been studied in a large number of
genetically-modiﬁed animals.
Regulators of chondrocyte hypertrophy-like changes and OA
A number of transgenic mouse strains, both knock outs and
transgenics, have been developed that support a role for chon-
drocyte terminal differentiation in the OA process. Genetic modiﬁ-
cations that stimulate chondrocyte hypertrophy-like changes are
frequently associated with a higher incidence of OA or accelerated
OA development. However, one has to keep in mind that many of
these genetic alterations might also affect bone and joint formation
and inﬂuence in this way OA development. Moreover, the obser-
vation that genetic modiﬁcations drive chondrocyte hypertrophy-
like changes and OA in mice, do not prove that these genes and
proteins play a part in human OA in the general population.
However, thesemodels provide insight in the regulation of cartilage
homeostasis and can point toward potential essential molecular
routes in OA (Table I).
Transcription factors
A number of transcription factors have been identiﬁed that
regulate chondrocyte differentiation and have an important role in
the transition to chondrocyte hypertrophy. Chondrocytehypertrophy is not under the strict control of a single transcription
factor but appears to be regulated by a regulatory network.
However, a pecking order of factors is likely, but the exact contri-
bution of different transcription factors to this process has not been
elucidated yet. However, it is clear that Runx2 is indispensable for
chondrocyte terminal differentiation.
Runx2 is a master transcription factor involved in chondrogenic
differentiation and completely controls chondrocyte hypertrophic
differentiation11,81. A core Runx2 regulated element is present in
the type X collagen promotor82. Runx2 expression is elevated in OA
cartilage in humans and experimental models11,78,82. What is more,
heterozygous RUNX-2-deﬁcient mice show, after surgical induction
of knee joint instability, decreased OA severity and reduced type X
collagen and MMP13 expression78.
Hypoxia-inducible factor-2alpha (HIF-2alpha) is a transcription
factor that is highly expressed in human OA cartilage and experi-
mental murine OA83. HIF-2alpha is important for chondrocyte
terminal differentiation. HIF-2alpha, encoded by the gene EPAS1, is
a very potent transactivator of COL10A184. It has been shown that
HIF-2alpha enhances promoter activities of COL10A1, MMP13 and
VEGF through speciﬁc binding to hypoxia-responsive elements.
Epas1-heterozygous mice showed resistance to OA development
and chondrocyte-speciﬁc Epas1 transgenic mice demonstrated
spontaneous cartilage destruction. These results indicate that
HIF-2alpha causes cartilage destruction by stimulating chondrocyte
terminal differentiation andup regulation of catabolic enzymes83,84.
Another transcription factor that has been suggested to be
involved in chondrocyte terminal differentiation and OA is CCAAT/
enhancer-binding protein beta (C/EBPbeta)85. Mouse embryos and
isolated chondrocytes with a homozygous deﬁciency in C/EBPbeta
exhibited delayed chondrocyte hypertrophy. In contrast, over-
expression of C/EBPbeta in chondrocytes enhanced hypertrophy.
Cartilage destruction in instability-induced OA in C/EBPbeta
heterozygous was less severe than in wild type mice85.
Recently, it was reported that C/EBPbeta co-localizes with the
regulatory protein Growth arrest and DNA damage-inducible
protein 45beta (GADD45beta) in aging articular chondrocytes in
senescence-accelerated mice (SAMP1) mice86. GADD45beta is
a BMP-2 early response gene, via the Smad1/Runx2 route, and an
essential mediator of MMP13 expression during terminal
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hypertrophic chondrocytes and early OA but not in late stage OA88.
Nuclear factor of activated T cells 1 (Nfat1) is a transcription
factor of a family that has been known to regulate gene transcrip-
tion in response to T cell receptor-mediated signals in lymphocytes.
However, the function of Nfat1 appears not be restricted to
lymphocytes, Nfat1 knock out mice show OA development and
elevated MMP13 and type X collagen levels at age 3 months and
older. Interestingly, in these mice elevated type X collagen
expressionwas associated with increased expression of Ctnnb1, the
gene encoding the wnt signaling molecule b-catenin90.
Transgenic mouse models show that both decreased and
elevated levels of b-catenin result in cartilage damage62,91. Over-
expression of b-catenin led to high expression of hypertrophy
markers (e.g., MMP13, type X collagen) by articular chondrocytes
while conditional knock down of b-catenin led to chondrocyte
apoptosis62,91. Both models showed cartilage destruction, but the
model showing elevated b-catenin levels and elevated hypertrophy
markers demonstrated a pattern of joint destruction more similar
to spontaneous OA. Elevated canonical wnt signaling drives OA
development by increasing Runx2 activity thereby boosting
hypertrophic differentiation of chondrocytes92e94.
Wnt signaling during chondrocyte hypertrophy is modulated by
other extra- and intracellular proteins. It has been shown that
TGF-b and BMP signaling is modulated by wnt signaling, most
probably by modulation of Smad signaling95e98. Moreover, Sox9
and b-catenin interact in their control of chondrocyte differentia-
tion. Sox9 and b-catenin reciprocally inﬂuence each others degra-
dation and compete in combination with TCF-LEF with promotor
binding sites associated with chondrocyte differentiation99,100.
The Smads are the most important transcription factors of the
TGF-b superfamily, a family that contains amongst other the
TGF-b’s and the BMPs. Smads play an important role in all aspects of
chondrocyte differentiation. These factors control chondrocyte
hypertrophy by modulating the function of Runx2. Smads are
phosphorylated by TGF-b superfamily type I receptors (activin-like
kinases, ALKs). The ALKs determine which Smads are phosphory-
lated; Smad2 and 3 are phosphorylated by ALK4, 5 or 7 and Smad1,
5 or 8 by ALK1, 2, 3 or 6. In chondrocytes it has been shown that
TGF-b can activate both ALK5 and ALK1, activating different
response genes, as demonstrated by Finsson et al. and our own
group101,102. Smad2 and 3 are essential signaling molecules in the
inhibitory effect of TGF-b on chondrocyte hypertrophy and Smad3
appears to play a more prominent role than Smad2103. While
terminal differentiation is blocked by signaling via Smad2/3,
hypertrophy strictly requires Smad1/5/8 signaling104. Moreover, in
knock out mice it was shown that loss of both Smad1 and 5 results
in blocking of chondrocyte hypertrophy. Furthermore, Smad6 and
Smurf1 and 2 are known inhibitors of mainly Smad1/5/8 signaling
and accelerate proteosomal breakdown of phospho-Smads. Mice
overexpressing either Smad6 or Smurf1 demonstrated inhibition of
chondrocyte hypertrophy105. Smads modulate chondrocyte differ-
entiation by a physical interaction with Runx2. Complex formation
of Runx2 with Smad1 is crucial for the function of Runx2 while
interaction of Smad3with Runx2 inhibits Runx2 functioning106e114.
Apparently, Runx2 is a switch that is either activated or inhibited by
different Smads, in this way determining chondrocyte hypertrophy.
We have observed an age-related loss of ALK5 and Smad2/3
phosphorylation in murine articular cartilage and in two experi-
mental OA models, the DMM (meniscus destabilization) model and
STR/ORTmice (spontaneousOA)115. Expressionofnon-phosporylated
Smad2 or Smad3 was not different in young and old animals. Inter-
estingly, expression of the alternative TGF-b receptor, ALK1, did not
diminish to a similar extent as ALK5 during aging and experimental
OA102. In addition, overexpression of constitutively active ALK1 inchondrocytes resulted in increased expression of MMP13102. More-
over, inhibition of ALK5 expression using siRNA resulted in elevated
expression of MMP13. These observations indicate that ALK1
signaling, via Smad1/5/8, stimulates hypertrophy-like changes in
articular chondrocytes.
Non transcription factors
A number of transcription factors of which Runx2 is essential
controls chondrocyte hypertrophy. However, other molecules are
known to control chondrocyte hypertrophy-like changes. The
Discoidin Domain Receptor 2 (DDR2) is a receptor tyrosine kinase
that is activated by collagen binding and has been proposed to
play a role in OA116. Progression of cartilage degeneration in
haploinsufﬁcient DDR2 mice with surgically-induced OA was
strikingly reduced117. Recently it was found that during osteogenic
differentiation DDR2 regulates the transactivity of Runx2 by
modulating its phosphorylation118. DDR2 increased Runx2 trans-
activation and stimulated type X collagen expression in ADTC5
cells-derived hypertrophic chondrocytes118. However, merely over
expression of DDR2 in murine cartilage does not lead to cartilage
degradation119. Only when the pericellular matrix is degraded, for
instance by the serine protease HtrA1, DDR2 can be activated by
type II collagen binding119,120. Expression of HtrA1 in chon-
drocytes is suggested to be induced by excessive loading, but has
also been shown to be associated with chondrocyte terminal
differentiation28,120.
Matrilin-3 is a non-collagenous pericellular matrix protein of
which mutations have shown to be involved in early onset OA121.
Matrilin-3 deﬁcient mice showed in the embryonic growth plate of
the developing long bones chondrocytes that prematurely became
prehypertrophic and hypertrophic122. However, at birth matrilin-3
deﬁcient mice showed no gross skeletal malformations. However,
old matrilin-3 knock out mice showed a higher incidence of severe
OA. Apparently, matrilin-3 deﬁciency increases chondrocyte
hypertrophy-like changes and leads to a higher incidence of OA.
SirT1 is a histone deacetylase that regulates gene expression,
and SirT1 has been implicated as a key factor in aging-related
diseases123. In human cartilage, SirT1 was hardly detectable in
severely degenerated areas while SirRT1 was clearly expressed in
less damaged regions124. Inhibition of SirT1 by siRNA induced
expression of chondrocyte hypertrophy markers, namely a signiﬁ-
cant up regulation of COL10A1. This is in line with studies showing
that SirT1 protects against chondrocyte apoptosis, a hallmark of
chondrocyte terminal differentiation125,126.These observations
suggest that SirT1 expression decreases with OA development of
OA and that decrease of SirT1 in chondrocytes causes chondrocyte
hypertrophy and cartilage degeneration.
TG-2 belongs to a family of protein cross-linking enzymes.
Increased TG-2 expression is found in human and experimental
OA127. In an instability-induced murine OA model it was found that
TG-2 deﬁcient mice had reduced cartilage destruction but
increased osteophyte formation compared to wild type mice127.
Chondrocytes from TG-2 knock out mice lost the capacity to
undergo hypertrophic differentiation induced by retinoic acid23.
This indicates that TG-2 knock out mice are protective to OA due to
a diminished capacity for chondrocyte hypertrophy-like changes.
Besides these single factors, it becomes more and more clear
that inﬂammatory factors can accelerate chondrocyte hypertrophy.
Inﬂammatory factors such as interleukin-8, ligands for RAGE
receptors like the S100 proteins, and NFkB signaling components all
appear to play a role in the regulation of chondrocyte terminal
differentiation108e111,114. A lingering, (sub)clinical inﬂammatory
reaction in the joint might in this way contribute to the unwanted
terminal differentiation of articular chondrocytes.
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differentiation, also mechanical stress, direct or indirect via soluble
mediators, can stimulate terminal differentiation. A review on
mechanics and chondrocyte hypertrophy by Donkelaar and Wilson
has recently been published128.
Apparently, chondrocyte terminal differentiation canbeenhanced
by a variety of stimuli and regulated intra-cellularly by a number of
transcription, and other, factors with a central role for Runx2 (Fig. 1).
The default route of chondrocyte differentiation appears to be
terminaldifferentiation, adestiny that isblocked inyoungandhealthy
articular cartilage. Inhibition of chondrocyte hypertrophy is a highly
regulated process. Primary OA is an age-related disease. Aging is
associated with an increase in “chaos”, and as a consequence of this
related to a loss in regulatory control of biological processes129e132.
Therefore, it can be postulated that during aging the active inhibition
of chondrocyte terminal differentiation is lost and that chondrocytes
regain their default differentiation route leading to hypertrophy-like
changes. Although an attractive concept, this model is not very easy
to prove experimentally.Chondrocyte hypertrophy-like changes in a conceptual model
of human primary, aging-related OA
Human primary OA is an age-dependent, slowly progressive
disease. It is clear that several subgroups of primary OA exist in the
human population with, until now not fully deﬁned, different
characteristics. However, alterations in chondrocyte behavior
appear to take a central position in the OA disease process. On the
other hand, alternative routes, not chondrocyte-centered, are put
forward that might lead to OA.
In OA, different phases can be recognized that are not only
different in timing but that can occur simultaneously within a joint,
but at different locations (Fig. 2). In this way creating in a particular
OA joint a mixture of processes and cellular reactions. It should beFig. 1. Factors regulating chondrocyte hypertrophic-like changes and produced by these cho
proteins that are involved in tissue remodeling and calciﬁcation. A number of (transcription
differentiated chondrocyte. Factors shown to be involved in OA-related hypertrophy-like chclear that the early stages (initiation and progression stage) will not
be diagnosed as clinical OA. Furthermore, one should keep in mind
that this conceptual model is only appropriate for primary,
age-related OA, and that even for this speciﬁc subgroup alternative
pathogenic routes are possible.
Initiation stage
A full-grown joint of a young adult starts as a healthy organwith
homeostasis of the various tissues in this organ. In the articular
chondrocytes of this joint, the step to hypertrophy-like changes is
actively blocked, amongst other by TGF-b. During aging, the
behavior of the chondrocytes alters and a subset of cells acquires
a phenotype that resembles that of hypertrophic chondrocytes,
producing MMP13. A striking age-related change in articular
cartilage is the loss of ALK5 and Smad2/3 phosphorylation. Phos-
phorylated Smad3 is a known blocker of chondrocyte hypertrophy.
Moreover, HtrA1 a broad-substrate enzyme involved in degrada-
tion of the pericellular matrix and expressed in early experimental
OA and hypertrophic chondrocytes, is a potent blocker of TGF-b
signaling28,120,133,134. Which cells acquire an altered behavior, and
when, is dependent on a number of variables such as genetic
constitution, joint loading, joint architecture, presence of inﬂam-
matory stimuli and stochastic processes.
Progression stage
ReleaseandactivationofHtrA1,MMP13andaggrecanaseswill lead
to degradation of the pericellular and intercellular matrix. Focal
release of proteoglycans will make collagen more vulnerable to
proteolytic degradation. Exposure of the type II collagen matrix will
inﬂuence chondrocytes byanalteredbiomechanical environment and
changes in chondrocyte differentiation via the DDR2 receptor, stim-
ulating hypertrophy-like changes. This process is a self-perpetuatingndrocytes. Chondrocytes that undergo hypertrophy-like changes produce a number of
) factors regulate the differentiation from a normal articular chondrocyte to a terminal
anges are shown.
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Fig. 2. Chondrocyte hypertrophy-like changes in a conceptual model of human primary OA. Cells that have acquired a “hypertrophy-like” phenotype (black) play an essential role
in cartilage breakdown by synthesis of MMP13 and ADAMTS4 and 5. TGF-b acts as a chondroprotective factor in young healthy cartilage but looses this action during aging.
Chondrocytes in clones neighboring cartilage damage are involved in an unsuccessful attempt at repair, but also contribute to further damage by release of proteolytic enzymes. Of
note, besides TGF-b numerous other signaling molecules, enzymes and matrix molecules are involved in the OA disease process.
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chondrocyte hypertrophic alterations. In addition, synovial activation,
triggered by damage-associated breakdown products, will lead to
production of inﬂammatory cytokines and growth factors, further
boosting changes in chondrocyte behavior and subsequent cartilage
damage. Factors released from the damaged cartilage matrix and the
activated synovial cells will attract inﬂammatory cells, such as
macrophages, andwill stimulate synovial ﬁbrosis. Moreover, elevated
levels of TGF-bwill set off osteophyte formation, originating from the
mesenchymal precursor cells in the periosteum.
Late stage
The cartilage contains sites that are heavily damaged. Cartilage
neighboring the damaged locations contains a population of chon-
drocytes that appears to be involved in an attempt to repair the
damage. Thesecells, that showsignsof cellproliferation, are located in
clusters and show high levels of Smad2/3 and Smad1/5/8 phosphor-
ylation (own data, not shown). The latter is indicative of activation of
these cells by members of the TGF-b superfamily. Apparently,
different chondrocyte population canbediscriminated: chondrocytes
that do not show Smad phosphorylation in the less damaged areas of
OA cartilage and cells surrounding damage cartilage displaying clear
Smadphosphorylation.Thesecells, althoughappearing tobe involved
in an attempt at repair, probably contribute to further cartilage
damage by their activated characteristics, exempliﬁed by elevated
MMP13 production. It seems that this population of “repair” cells is
only present in the highly damaged areas since more intact human
cartilage do not show these cell clusters.
End stage
The end-stage will be a mixture of eburnated bone without
cartilage, severely damaged cartilage with clefts and ﬁssures, less
damaged ﬁbrillated cartilage and cartilage that looks histologicallyrelatively normal. In severely damaged cartilage, chondrocyte
clusters are found. At the joint margins, calciﬁed osteophytes are
present and the synovial tissue is activated, showing inﬁltrated
inﬂammatory cells, cell proliferation and ﬁbrosis. Due to the altered
biomechanics and release of cytokines and growth factors, the
subchondral bone has become sclerotic and shows focal bone cysts.
This is the general picture that one gets from end-stage OA cartilage
obtained during joint arthroplasty.
The initiation stage is age-dependent and driven by chondrocyte
senescence such as changes in chondrocyte receptor expression,
maybe because of changes in genemethylation.When the initiation
stage is ongoing and irreversible cartilage damage is inﬂicted
(damage to the collagen matrix), the process is a slow but
self-perpetuating process mediated by a self-enhancing loop of
changes in chondrocyte behavior (hypertrophy-like) and increasing
damage to the cartilage matrix. On top of this, neighboring
damaged cartilage, chondrocytes are triggered to overcome the
damage. However, these cells apparently further contribute to the
OA process by the production of MMP13.
Primary OA is a slow, age-related, disease process with a mix of
disease stages and cellular responses within a joint. This and the
fact that only end-stage human OA cartilage is readily available
make reproducible tissue sampling a complicated task. Although
most studies report hypertrophy-like changes in OA chondrocytes,
the latter could be the explanation for variability between different
ﬁndings. Alternatively different patient groups exist, with and
without hypertrophic changes. Since chondrocyte behavior is not
synchronized in an OA joint, and OA starts as a focal process,
inhibition of chondrocyte hypertrophy-like alterations could be
a therapeutic target to block further OA progression.Author contributions
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